| Literature DB >> 28583124 |
Ellen Winckelmans1, Karen Vrijens1, Maria Tsamou1, Bram G Janssen1, Nelly D Saenen1, Harry A Roels1,2, Jos Kleinjans3, Wouter Lefebvre4, Charlotte Vanpoucke5, Theo M de Kok3, Tim S Nawrot6,7.
Abstract
BACKGROUND: Air pollution exposure during pregnancy has been associated with adverse birth outcomes and health problems later in life. We investigated sex-specific transcriptomic responses to gestational long- and short-term exposure to particulate matter with a diameter < 2.5 μm (PM2.5) in order to elucidate potential underlying mechanisms of action.Entities:
Keywords: Ambient air pollution; Fetal; Microarray analysis; Particulate matter; Sex
Mesh:
Substances:
Year: 2017 PMID: 28583124 PMCID: PMC5458481 DOI: 10.1186/s12940-017-0264-y
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Demographic characteristics of the study population and exposure (n = 142)
| Characteristic | Mean (p10, p90) |
|---|---|
| Mothers | |
| Age, yrs | 29.3 (24.0, 34.0) |
| Pre-gestational BMI, kg/m2 | 24.2 (19.5, 30.5) |
| Education | |
| Low | 15 (10.6%) |
| Medium | 50 (35.2%) |
| High | 77 (54.2%) |
| Smoking status | |
| Never-smoker | 80 (56.3%) |
| Former-smokers | 36 (25.4%) |
| Smokers | 26 (18.3%) |
| Alcohol consumption | |
| No | 119 (83.8%) |
| Occasionally | 23 (16.2%) |
| Parity | |
| 1 | 70 (49.3%) |
| 2 | 59 (41.5%) |
| ≥ 3 | 13 (9.2%) |
| Newborns | |
| Sex | |
| Boys | 66 (46.5%) |
| Season at conception | |
| Winter | 38 (26.8%) |
| Spring | 40 (28.2%) |
| Summer | 37 (26.1%) |
| Autumn | 27 (19.0%) |
| Ethnicity | |
| European-Caucasian | 124 (87.3%) |
| Gestational age, wks | 39.7 (38.3, 41.1) |
| Birth weight, g | 3454 (2910, 4045) |
| Exposure | |
| Long-terma PM2.5, μg/m3 | 16.0 (13.9, 18.3) |
| Short-termb PM2.5, μg/m3 | 13.3 (8.0, 21.4) |
| Weekly apparent temp, °C | 8.9 (2.4, 16.5) |
p percentile
aAnnual average before delivery. bLast month of pregnancy
Top 15 overrepresented pathways associated with long-term PM2.5 exposure for girls and boys
| Sex | Pathway | Effective/total size | # ↓ genes | Contributing genes |
|
|---|---|---|---|---|---|
| Girls | |||||
| Generic Transcription Pathwaya | 367/478 | 80 | Top 5 out of 33 significant genes: ZNF124↑; MED16↑; KRBA1↑; ZNF205↓; ZNF720↑ | 3.0E-06 | |
| Defensins | 19/53 | 15 | ART1↓;DEFA3↓; | 5.7E-04 | |
| Binding and Uptake of Ligands by Scavenger Receptorsa | 28/43 | 15 | APOA1↓; HPR↓; HP↓; HBA2↑; FTL↑ | 3.6E-03 | |
| agrin in postsynaptic differentiation | 39/47 | 18 | EGFR↑; PTK2↑; UTRN↑; ITGB1↑; CHRM1↓ | 1.5E-02 | |
| JAK-STATa | 39/43 | 15 | PTK2↑; ESR1↓; ZAP70↑;PDK1↑; ITGB1↑ | 1.5E-02 | |
| ATM Signaling Pathwaya | 15/18 | 7 | ATM↑;ATF2↑;RAD51↓ | 1.7E-02 | |
| Integrated Pancreatic Cancer Pathway | 141/165 | 62 | SERPINB10↓;CAMP↓;RAD51↓;TYMS↓;INHBA↓; | 1.8E-02 | |
| Transcriptional misregulation in cancer - | 146/179 | 73 | CEBPE↓; CDKN2C↓; EWSR1↑; DEFA3↓; HIST1H3J↓; PTK2↑; ASPSCR1↓; MPO↓; NTRK1↓; ELANE↓; ATM↑ | 2.3E-02 | |
| BARD1 signaling events | 29/29 | 17 | RAD51↓;ATM↑;EWSR1↑;UBE2D3↑ | 2.3E-02 | |
| Gastric cancer network 2 | 29/32 | 9 | CACYBP↑;AHCTF1↑;EGFR↑;BRIX1↑ | 2.3E-02 | |
| Extracellular matrix organization | 167/275 | 92 | ITGB1↑; ELANE↓; MMP17↓; LTBP3↑; PLOD1↑; CTSG↓; CEACAM1↓; MMP8↓; CEACAM6↓; CEACAM8↓; COL17A1↓ | 2.5E-02 | |
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | 32/45 | 15 | CTSG↓;EGFR↑;ELANE↓;ITGB1↑ | 3.2E-02 | |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 20/21 | 3 | UBA52↑; TGIF2↑; PPM1A↑ | 3.8E-02 | |
| JAK-STAT-Core | 67/104 | 29 | IL11RA↑; IL12RB1↑; STAT4↑; MPL↑; EGFR↑; IL6ST↑ | 4.1E-02 | |
| Boys | |||||
| TNF receptor signaling pathway | 44/48 | 29 | IKBKB↑; MAP4K5↑; TAB2↑; TAB1↓; MAP2K3↑; TNIK↓; TNF↓; IKBKG↑; GNB2L1↓ | 4.8E-03 | |
| Mercaptopurine Action Pathway | 38/47 | 21 | ATIC↓; PAICS↓; TPMT↓; APRT↓; ITPA↓; ADA↓; ABCC4↓; ADSL↓ | 6.5E-03 | |
| Primary immunodeficiency - Homo sapiens (human) | 32/36 | 25 | ICOS↓; ORAI1↓; CD40LG↓; IKBKG↑; ADA↓; CD3D↓; LCK↓ | 8.6E-03 | |
| the co-stimulatory signal during t-cell activation | 18/21 | 13 | CTLA4↓; ICOS↓; CD3D↓; LCK↓; ITK↓ | 9.0E-03 | |
| FCERI mediated NF-kB activationa | 19/63 | 13 | IKBKB↑; TAB2↑; TAB1↓; RASGRP1↓; IKBKG↑ | 1.1E-02 | |
| p73 transcription factor network | 68/81 | 38 | GNB2L1↓; PFDN5↑; PLPP1↓; UBE4B↑; TP73↓; BAK1↓; FOXO3↑; ADA↓; MDM2↑; BIN1↓; MYC↓ | 1.2E-02 | |
| Axon guidance - Homo sapiens (human)a | 88/127 | 57 | EPHB2↓; EPHB3↓; ROBO2↓; PPP3R1↑; ROBO3↓; EFNA4↓; EFNA3↓; ROCK1↑; EPHA1↓; ITGB1↑; RGS3↓; ABLIM1↓; SEMA4C↓ | 1.4E-02 | |
| Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics | 28/32 | 22 | PRPS1↓; TPMT↓; NT5E↓; ITPA↓; ADA↓; ABCC4↑ | 1.6E-02 | |
| T cell receptor signaling pathway - Homo sapiens (human) | 91/104 | 59 | DLG1↑; CTLA4↓; ICOS↓; RASGRP1↓; CD40LG↓; ITK↓; PPP3R1↑; IKBKB↑; TNF↓; CDK4↓; IKBKG↑; CD3D↓; LCK↓ | 1.8E-02 | |
| Oncogene Induced Senescencea | 29/31 | 13 | TP53↓; E2F2↑; CDK4↓; TFDP1↑; MDM2↑; AGO3↑ | 1.9E-02 | |
| Regulation of nuclear beta catenin signaling and target gene transcription | 64/81 | 39 | TCF7↓; HDAC2↓; TBL1XR1↑; AES↓; CAMK4↓; TNIK↓; APC↑; MYC↓; LEF1↓; AXIN2↓ | 2.1E-02 | |
| TP53 Network | 15/18 | 7 | MDM2↑; TP53↓; MYC↓; TP73↓ | 2.2E-02 | |
| Bladder Cancer | 23/26 | 14 | CDK4↓; TYMP↓; MDM2↑; TP53↓; MYC↓ | 2.6E-02 | |
| Stimuli-sensing channels | 68/102 | 38 | TRPV6↓; CLCN3↑; WNK2↓; TRPM5↓; CLCN7↑; ANO10↓; TPCN1↑; BEST4↓; WWP1↓; WNK1↑ | 3.0E-02 | |
| Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human) | 41/51 | 23 | NEFH↓; PPP3R1↑; TOMM40↓; TNF↓; BCL2L1↑; MAP2K3↑; TP53↓ | 3.2E-02 |
# ↓ genes: number of down-regulated genes. aPathways that remain significant in the sensitivity analysis
Top 15 overrepresented pathways associated with short-term PM2.5 exposure for girls and boys
| Sex | Pathway | Effective /total size | # ↓ genes | Contributing genes |
|
|---|---|---|---|---|---|
| Girls | |||||
| mRNA Processinga | 124/126 | 32 | PTBP2↑; SRSF1↑; SFPQ↑; SNRNP40↑; CELF1↑; HNRNPU↑; TRA2B↑; SRSF6↑; HNRNPH1↑; PRPF40A↑ | 1.9E-03 | |
| Ephrin signaling | 16/22 | 5 | NCK2↑; SDCBP↑; ARHGEF7↑ | 8.4E-03 | |
| Ectoderm Commitment Pathwaya | 87/129 | 30 | PDE7A↑; SDCBP↑; MZF1↑; C1GALT1↑ NF2↑; OGT↑; TSC22D1↑ | 9.1E-03 | |
| IL-4 Signaling Pathwaya | 52/53 | 27 | IKBKB↑; PTPN11↑; IL2RG↓; ATF2↑; RPS6KB1↑ | 1.3E-02 | |
| Physiological and Pathological Hypertrophy of the Hearta | 20/24 | 8 | IL6ST↑; CAMK2D↑; PPP3CB↑ | 1.6E-02 | |
| miR-targeted genes in lymphocytes - TarBase | 362/482 | 108 | Top 5 out of 17 genes: MBNL1↑; SUCLG2↑; TGFBR2↑; GTPBP3↑; DMTF1↑ | 1.9E-02 | |
| Basal transcription factors - Homo sapiens (human)a | 39/45 | 13 | TAF8↑; GTF2H2C_2↑; TAF1↑; TAF11↑ | 2.1E-02 | |
| Spliceosome - Homo sapiens (human)a | 127/130 | 33 | HNRNPU↑; PRPF40A↑; RBM25↑; SNRNP40↑; THOC1↑; SRSF1↑; SRSF6↑; TRA2B↑ | 2.2E-02 | |
| Activated TLR4 signalinga | 110/120 | 47 | ATF2↑; SIGIRR↑; IL6ST↑; PTPN11↑; IKBKB↑; IRF3↑; UBE2D3↑ | 2.9E-02 | |
| Insulin Pathway | 44/47 | 13 | RPS6KB1↑; PTPN11↑; NCK2↑; EXOC7↑ | 3.0E-02 | |
| Salmonella infection - Homo sapiens (human) | 68/86 | 38 | PFN1↓; RAB7A↓; DYNC1H1↑; WAS↓; PKN2↑ | 3.7E-02 | |
| Amphetamine addiction - Homo sapiens (human)a | 48/68 | 21 | PPP3CB↑; CAMK2D↑; ATF4↑; ATF2↑ | 4.0E-02 | |
| Generic Transcription Pathway | 367/478 | 91 | Top 5 out of 16 genes: ZNF625↑; ZNF37A↑; ZNF419↑; ZNF205↓; ZNF12↑ | 4.0E-02 | |
| Direct p53 effectorsa | 123/147 | 47 | PMS2↑; KAT2A↑; BNIP3L↑; TGFA↓; PIDD1↑; AIFM2↑; HIC1↓ | 4.9E-02 | |
| Boys | |||||
| Lidocaine (Local Anaesthetic) Action Pathwaya | 19/31 | 13 | CYP3A4↓; CACNA2D2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ADRA1A↓ | 9.9E-04 | |
| Signaling events mediated by PRLa | 20/23 | 4 | CDK2↑; BCAR1↓; RABGGTA↑; PTP4A3↑; ROCK1↑; ITGB1↑ | 1.3E-03 | |
| Protein processing in endoplasmic reticulum - Homo sapiens (human)a | 156/168 | 36 | Top 5 out of 19 significant genes: ATF4↑; SEC31A↑; UBQLN3↓; UGGT1↑; CRYAB↓ | 6.2E-03 | |
| Basigin interactionsa | 19/30 | 6 | ATP1B3↑; SLC3A2↑; ATP1B1↑; CAV1↓; ITGB1↑ | 6.3E-03 | |
| Morphine Action Pathwaya | 27/44 | 16 | DNAJB11↑; CACNA2D2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ADRA1A↓ | 6.9E-03 | |
| mRNA Splicing - Major Pathwaya | 116/131 | 14 | Top 5 out of 15 significant genes: SMC1A↑; PCBP1↑; PRPF8↑; SNRPA↓; CD2BP2↑ | 8.3E-03 | |
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | 30/37 | 11 | ATF4↑; TXLNG↑; LAMA3↓; NFATC3↑; USF2↑; CDKN2A↓ | 1.2E-02 | |
| Maturity onset diabetes of the young - Homo sapiens (human) | 15/25 | 14 | NR5A2↓; PAX4↓; FOXA2↓; GCK↓ | 1.4E-02 | |
| Hedgehog ligand biogenesisa | 15/21 | 5 | OS9↑; DISP2↓; P4HB↑; VCP↑ | 1.4E-02 | |
| Salivary secretion - Homo sapiens (human)a | 60/90 | 28 | ADCY3↓; ADRA1A↓; NOS1↓; GUCY1A3↑; PRH2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ATP2B3↓ | 1.5E-02 | |
| Processing of Capped Intron-Containing Pre-mRNAa | 147/162 | 18 | Top 5 out of 17 significant genes: SMC1A↑; RANBP2↑; PCBP1↑; PRPF8↑; SNRPA↓ | 1.5E-02 | |
| G. alpha (s) signaling eventsa | 81/129 | 44 | ADCYAP1R1↓; CALCA↓; PTH2↓; ADCY3↓; GNAZ↓; TSHB↓; INSL3↓; TAAR2↓; GHRHR↓; GLP2R↓; GNG13↓ | 1.6E-02 | |
| Neuroactive ligand-receptor interaction - Homo sapiens (human) | 164/275 | 102 | GABRG2↓; GABRP↓; NTSR2↓; TAAR2↓; TSHB↓; CHRM5↓; ADCYAP1R1↓; GH1↓; GHRHR↓; HTR1B↓; ADRA1A↓; GLP2R↓; THRA↓; ADORA1↓; CHRNA2↓; LPAR1↑; OPRL1↓; GRM5↓ | 2.1E-02 | |
| FOXM1 transcription factor network | 34/42 | 10 | CDK2↑; XRCC1↑; CENPF↑; NFATC3↑; TGFA↓; CDKN2A↓ | 2.1E-02 | |
| TCA Cycle | 17/17 | 4 | FH↑; MDH2↑; OGDH↑; IDH2↑ | 2.2E-02 | |
# ↓ genes: number of down-regulated genes. aPathways that remain significant in the sensitivity analysis
Pathways modulated by long-term PM2.5 exposure for girls and boys resulting from GSEA
| Sex | Cluster label | Source: pathway | # genes | Direction of regulation |
|---|---|---|---|---|
| Girls | Aurora B pathway | PID: Aurora B pathway | 36 | DOWN |
| Core matrisome | Matrisome: Naba core matrisome | 142 | DOWN | |
| Defensins | Reactome: defensins | 18 | DOWN | |
| Extracellular matrix organization | DOWN | |||
| Reactome: extracellular matrix organization | 49 | |||
| Reactome: degradation of the extracellular matrix | 18 | |||
| FOXM1 pathway | PID: FOXM1 pathway | 32 | DOWN | |
| Histone related pathways | DOWN | |||
| Reactome: amyloids | 69 | DOWN | ||
| Reactome: RNA polymerase I promotor opening | 54 | DOWN | ||
| KEGG: systemic lupus erythematosus | 116 | DOWN | ||
| Olfactory signaling | DOWN | |||
| KEGG: olfactory transduction | 124 | DOWN | ||
| Reactome: olfactory signaling pathway | 95 | DOWN | ||
| Porphyrin metabolism | KEGG: porphyrin and chlorophyll metabolism | 25 | DOWN | |
| Ribosome related pathways | UP | |||
| Reactome: peptide chain elongation | 83 | |||
| KEGG: ribosome | 85 | |||
| Reactome: nonsense mediated decay enhanced by the exon junction complex | 104 | |||
| Transcription-SMAD2,3,4-TGFβ pathways | UP | |||
| Reactome: generic transcription pathway | 267 | |||
| Reactome: downregulation of SMAD2, 3, SMAD4 transcriptional activity | 18 | |||
| Reactome: signaling by TGF-beta receptor complex | 54 | |||
| Boys | Apoptotic execution | Reactome: apoptotic execution phase | 43 | UP |
| Cell cycle | UP | |||
| Reactome: cell cycle mitotic | 290 | |||
| Reactome: mitotic prometaphase | 79 | |||
| Reactome: DNA replication | 176 | |||
| HDAC class III | PID: HDAC class III pathway | 22 | UP | |
| UPA-UPAR pathway | PID: uPA uPAR pathway | 30 | UP | |
| RhoA pathway | PID: RhoA pathway | 37 | UP |
For clusters containing more than 3 pathways, only the top 3 significant pathways are given.
# gene: number of genes within a pathway. uPAR Urokinase-type plasminogen activator (uPA) receptor, HDAC histone deacetylase, FOXM1 forkhead box M1, RhoA Ras homolog gene family member A, PID Pathway Interaction Database, KEGG Kyoto Encyclopedia of Genes and Genomes
Pathways modulated by short-term PM2.5 exposure for girls and boys resulting from GSEA
| Sex | Cluster label | Source: pathway | # genes | Direction of regulation |
|---|---|---|---|---|
| Girls | Olfactory signaling | Reactome: olfactory signaling pathway | 95 | DOWN |
| Rho pathway | BioCarta: Rho pathway | 28 | DOWN | |
| Ribosome related pathways | UP | |||
| Reactome: nonsense mediated decay enhanced by the exon junction complex | 104 | |||
| KEGG: ribosome | 85 | |||
| Reactome: 3′ UTR mediated translational regulation | 102 | |||
| Boys | ATM pathway | PID: ATM pathway | 18 | UP |
| BARD1 pathway | PID: BARD1 pathway | 29 | UP | |
| Cell Cycle | UP | |||
| Reactome: DNA replication | 176 | |||
| Reactome: G2/M checkpoints | 37 | |||
| Reactome: cell cycle mitotic | 290 | |||
| ETC-TCA cycle | UP | |||
| Reactome: TCA cycle and respiratory electron transport | 113 | |||
| Reactome: respiratory electron transport atp synthesis by chemiosmotic coupling and heat production by uncoupling proteins | 79 | |||
| M-calpain pathway | BioCarta: M-calpain pathway | 21 | UP | |
| Metabolism of mRNA and RNA | UP | |||
| Reactome: metabolism of RNA | 249 | |||
| Reactome: metabolism of mRNA | 204 | |||
| Myc pathway | PID: Myc activ pathway | 76 | UP | |
| Olfactory signaling | DOWN | |||
| KEGG: olfactory transduction | 124 | |||
| Reactome: olfactory signaling pathway | 95 | |||
| mRNA processing | UP | |||
| Reactome: processing of capped intron containing pre mRNA | 133 | UP | ||
| Reactome: mRNA processing | 147 | |||
| Response to elevated platelet cytosolic CA2+ | Reactome: response to elevated platelet cytosolic CA2+ | 66 | UP | |
| Ribosome related pathways | UP | |||
| Reactome: translation | 141 | |||
| Reactome: SRP dependent cotranslational protein targeting to membrane | 105 | |||
| Reactome: 3′ UTR mediated translational regulation | 102 | |||
| RhoA pathway | PID: RhoA pathway | 37 | UP | |
| Splicesome | KEGG: spliceosome | 123 | UP |
For clusters containing more than 3 pathways, only the top 3 significant pathways are given
# genes: number of genes within a pathway. Rho Ras Homolog gene family, TCA tricarboxylic acid, ETC electron transport chain, ATM Ataxia Telangiectasia Mutated, BARD1 BRCA1 associated RING domain 1. Myc v-myc avian myelocytomatosis viral oncogene homolog, PID Pathway Interaction Database, KEGG Kyoto Encyclopedia of Genes and Genomes
Overview of selected biological processes altered by gestational PM exposure
ORA Overrepresentation Analysis. GSEA Gene Set Enrichment Analysis
Gray: PM2.5-related processes in the main analysis. SA: processes that remained significant in the sensitivity analysis. (SA)↑: most significant up-regulated pathways in the sensitivity analysis